|
TWEAK, a New Biomarker for Predicting Inflammatory Relapses in Multiple Sclerosis
RECRUITINGN/ASponsored by Assistance Publique Hopitaux De Marseille
Actively Recruiting
PhaseN/A
SponsorAssistance Publique Hopitaux De Marseille
Started2023-06-16
Est. completion2027-06-16
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03974997
Summary
A significant variation in the serum concentration of the circulating cytokine TWEAK is associated with the onset of an inflammatory attack of MS. Study the concentration variations of the serum soluble form of cytokine TWEAK during the first year of MS and to analyze their correlation with the occurrence of an inflammatory disease outbreak.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * a first episode of inflammation and demyelination of the central nervous system affecting the optic nerve, the spinal cord, one cerebral hemisphere, or the brainstem; or confirmed multiple sclerosis * no differential diagnosis at enrollment based on clinical examination and laboratory tests * compliance with the revised 2017 Mac Donald diagnostic criteria Exclusion Criteria: * age \<18 years old * person in an emergency situation * adult who is subject to a legal protection measure (an adult under guardianship, conservatorship, or judicial protection), or who is unable to give consent * not Enrolled in a Social Security Program * pregnant or breastfeeding woman
Conditions1
Multiple Sclerosis
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorAssistance Publique Hopitaux De Marseille
Started2023-06-16
Est. completion2027-06-16
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT03974997